Jan-Feb 2011 Table of Contents

LETTERS

Fam Pract Manag. 2011 Jan-Feb;18(1):4.

“Refills” for schedule II controlled substances?

In the article “A Proactive Approach to Controlled Substance Refills” [November/December 2010], the authors seem to describe proactive clerical prescription processing, but retroactive clinical medication monitoring. In the process, they misrepresent the new prescriptions they recommend writing without associated clinical assessments as prescription “refills.” The confusion created by the use of this terminology has substantial medicolegal and clinical ramifications, beginning with the fact that prescription refills for schedule II drugs are illegal: “The issuance of refills for a schedule II controlled substance is prohibited by law.”1

Drug Enforcement Administration regulations allow doctors to prescribe a sequence of up to three 30-day prescriptions in a single office visit. Following this simple, clinically proactive method would altogether eliminate the need for patients to pick up monthly “refills” from non-clinical intermediaries.

1. U.S. Department of Justice, Drug Enforcement Administration, Office of Diversion Control. Issuance of multiple prescriptions for schedule II controlled substances. Available at: http://www.deadiversion.usdoj.gov/faq/mult_rx_faq.htm. Accessed Dec. 15, 2010.

Authors' response:

Issuing a sequence of three time-delineated prescriptions during a single visit, as Dr. Teichman suggests, is certainly an acceptable option for providers. The method described in our article allows each separate prescription to be written and given to the patient in the time frame when it will be used, rather than giving multiple prescriptions to the patient at one time.

Our program of providing a separate prescription each month allows tighter surveillance with urine toxicology screening and physician oversight, which we have found beneficial. Our method does not involve refilling controlled substances on a single prescription, which, as Dr. Teichman mentions, is illegal for schedule II drugs.

WE WANT TO HEAR FROM YOU

Send your comments to fpmedit@aafp.org. Submission of a letter will be construed as granting AAFP permission to publish the letter in any of its publications in any form. We cannot respond to all letters we receive. Those chosen for publication will be edited for length and style.

Copyright © 2011 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact fpmserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • FPM CME Quiz

Information From Industry